Research and Markets: Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/gx996l/lexapro_major) has announced the addition of the "Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Lexapro (escitalopram) is an SSRI that was developed by Lundbeck; it initially gained marketing approval for MDD in 2002 in the US. Lexapro is the S-enantiomer of citalopram, an SSRI that was also developed by Lundbeck, which first became available in 1989. Lexapro acts by binding with high affinity to serotonin (5-HT), thereby inhibiting serotonin reuptake; this results in the higher levels of serotonin that are believed to exert antidepressant effects.

Scope

  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Lexapro including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Lexapro for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Lexapro (Escitalopram)

7 Appendix

For more information visit http://www.researchandmarkets.com/research/gx996l/lexapro_major

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System